Kari Sørland

632 total citations
10 papers, 205 citations indexed

About

Kari Sørland is a scholar working on Psychiatry and Mental health, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Kari Sørland has authored 10 papers receiving a total of 205 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 4 papers in Neurology and 2 papers in Cellular and Molecular Neuroscience. Recurrent topics in Kari Sørland's work include Fibromyalgia and Chronic Fatigue Syndrome Research (10 papers), Peripheral Neuropathies and Disorders (3 papers) and Long-Term Effects of COVID-19 (2 papers). Kari Sørland is often cited by papers focused on Fibromyalgia and Chronic Fatigue Syndrome Research (10 papers), Peripheral Neuropathies and Disorders (3 papers) and Long-Term Effects of COVID-19 (2 papers). Kari Sørland collaborates with scholars based in Norway, United Kingdom and Netherlands. Kari Sørland's co-authors include Øystein Fluge, Olav Mella, Ingrid G. Rekeland, Kine Alme, Kristin Risa, Olav Dahl, Ove Bruland, Dipak Sapkota, E. K. Kristoffersen and Alexander Fosså and has published in prestigious journals such as PLoS ONE, Clinical Therapeutics and JCI Insight.

In The Last Decade

Kari Sørland

9 papers receiving 199 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kari Sørland Norway 6 182 84 42 20 19 10 205
Ingrid G. Rekeland Norway 6 187 1.0× 84 1.0× 44 1.0× 20 1.0× 19 1.0× 10 207
Daniel Missailidis Australia 7 181 1.0× 76 0.9× 45 1.1× 32 1.6× 20 1.1× 10 228
Rosamund Vallings New Zealand 6 210 1.2× 90 1.1× 32 0.8× 15 0.8× 33 1.7× 8 252
Jared Stevens United States 9 204 1.1× 92 1.1× 24 0.6× 52 2.6× 14 0.7× 19 242
Victoria Strassheim United Kingdom 9 171 0.9× 76 0.9× 47 1.1× 33 1.6× 31 1.6× 15 289
Sharni Lee Hardcastle Australia 8 363 2.0× 104 1.2× 44 1.0× 57 2.9× 60 3.2× 12 396
Ruud CW Vermeulen Netherlands 8 228 1.3× 57 0.7× 46 1.1× 43 2.1× 36 1.9× 11 308
B. Greim Germany 9 76 0.4× 123 1.5× 41 1.0× 4 0.2× 9 0.5× 14 302
Elza Dias‐Tosta Brazil 9 61 0.3× 119 1.4× 34 0.8× 6 0.3× 16 0.8× 20 248
Jean‐Pierre Ndayisaba Austria 10 176 1.0× 106 1.3× 68 1.6× 18 0.9× 5 0.3× 19 315

Countries citing papers authored by Kari Sørland

Since Specialization
Citations

This map shows the geographic impact of Kari Sørland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari Sørland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari Sørland more than expected).

Fields of papers citing papers by Kari Sørland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kari Sørland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari Sørland. The network helps show where Kari Sørland may publish in the future.

Co-authorship network of co-authors of Kari Sørland

This figure shows the co-authorship network connecting the top 25 collaborators of Kari Sørland. A scholar is included among the top collaborators of Kari Sørland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kari Sørland. Kari Sørland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Fluge, Øystein, Ingrid G. Rekeland, Kari Sørland, et al.. (2025). Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study. Frontiers in Medicine. 12. 1607353–1607353.
2.
Rekeland, Ingrid G., Kari Sørland, Alexander Fosså, et al.. (2024). Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS ONE. 19(7). e0307484–e0307484. 3 indexed citations
3.
Sørland, Kari, et al.. (2023). Endothelial dysfunction in ME/CFS patients. PLoS ONE. 18(2). e0280942–e0280942. 19 indexed citations
4.
Rekeland, Ingrid G., Kari Sørland, Ove Bruland, et al.. (2022). Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients. PLoS ONE. 17(9). e0274472–e0274472. 5 indexed citations
5.
Hoel, Fredrik, Ina K. N. Pettersen, Ingrid G. Rekeland, et al.. (2021). A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. 6(16). 34 indexed citations
6.
Sørland, Kari, Ingrid G. Rekeland, Lis Ribu, et al.. (2021). Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome–Results From Open-Label Cyclophosphamide Intervention Study. Frontiers in Medicine. 8. 642710–642710. 23 indexed citations
7.
Rekeland, Ingrid G., Alexander Fosså, Kari Sørland, et al.. (2020). Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in Medicine. 7. 162–162. 22 indexed citations
8.
Giannoccaro, Maria Pia, Judith Cossins, Kari Sørland, Øystein Fluge, & Angela Vincent. (2019). Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics. 41(5). 836–847. 7 indexed citations
9.
Rekeland, Ingrid G., Øystein Fluge, Kine Alme, et al.. (2018). Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics. 41(5). 806–814. 3 indexed citations
10.
Fluge, Øystein, Kristin Risa, Kine Alme, et al.. (2015). B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PLoS ONE. 10(7). e0129898–e0129898. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ingrid G. Rekeland Breakdown of academic impact, for papers by Daniel Missailidis Breakdown of academic impact, for papers by Rosamund Vallings Breakdown of academic impact, for papers by Jared Stevens Breakdown of academic impact, for papers by Victoria Strassheim Breakdown of academic impact, for papers by Sharni Lee Hardcastle Breakdown of academic impact, for papers by Ruud CW Vermeulen Breakdown of academic impact, for papers by B. Greim Breakdown of academic impact, for papers by Elza Dias‐Tosta Breakdown of academic impact, for papers by Jean‐Pierre Ndayisaba
Rankless by CCL
2026